Amlodipine Dosing for Adults 65 and Older: Starting Low, Titrating Safely

Amlodipine besylate (brand name Norvasc, also available generically) is a long-acting dihydropyridine calcium channel blocker approved for hypertension and certain forms of angina. For most adults aged 65 and older, the FDA-approved label recommends starting at 2.5 mg once daily, half the usual adult starting dose, because slower hepatic clearance in older patients raises drug exposure at any given dose. This article covers what the label specifies, what guideline bodies recommend for blood pressure targets in older adults, and where clinical judgment has to fill gaps that trial evidence does not cover.

This is educational information for clinicians and patients preparing for a prescribing conversation. It is not individualized dosing advice, and no dose change should be made without a clinician who knows the patient's kidney and liver function, other medications, fall history, and blood pressure trend.

The direct answer

The FDA label for amlodipine besylate recommends a starting dose of 2.5 mg once daily in patients 65 and older, in small or fragile patients, and in patients with hepatic insufficiency, compared with the standard 5 mg starting dose for other adults. The maximum approved dose is 10 mg once daily regardless of age. Dose increases should generally be spaced at least a week apart because amlodipine takes about that long to reach steady-state blood levels, so an earlier increase risks stacking doses before the true effect of the prior one is visible. Blood pressure targets in older adults are guideline-dependent and not uniform: the 2017 ACC/AHA hypertension guideline generally favors a target below 130/80 mmHg for community-dwelling adults who tolerate treatment, while the 2017 ACP/AAFP guideline favors a less aggressive target of below 150 mmHg systolic for many adults 60 and older, particularly those who are frail or have limited life expectancy. Choosing between these targets is a matter of individualized judgment, not a single correct number.

Why the starting dose is lower in older adults

Amlodipine is cleared mainly through hepatic metabolism (largely via CYP3A4). Age-related reductions in liver blood flow and enzyme activity slow this process, and the drug's elimination half-life is already long (on the order of 30 to 50 hours) even in younger adults, extending further in older patients and in hepatic impairment. The FDA label states that elderly patients have reduced clearance of amlodipine, with a resulting increase in area under the curve, and it is on this basis that the label sets 2.5 mg as the recommended starting dose for patients 65 and older (FDA prescribing information). The label does not attach a single precise percentage increase in exposure across all older patients, and pharmacokinetic studies reporting an exact figure (for example, a specific percentage increase in Cmax) should be confirmed against the primary literature before being repeated as a fixed number in clinical materials.

The practical consequence is straightforward even without a precise number: a standard adult dose given to an older patient produces higher and longer-lasting drug levels than the same dose in a younger patient, which raises the risk of hypotension, dizziness, and peripheral edema if titration is rushed.

How fast should the dose be increased?

Amlodipine reaches steady-state plasma concentration in about 7 to 8 days at any given dose, per the FDA label. This is the pharmacologic reason clinicians wait at least a week, and often two, before judging whether a dose is working. A reasonable titration sequence, consistent with the label's low-and-slow approach for older adults, looks like this:

1. Start at 2.5 mg once daily.
2. Recheck seated and standing blood pressure no sooner than 7 to 14 days later.
3. If blood pressure remains meaningfully above the individualized target, increase to 5 mg daily and recheck again after a similar interval.
4. If further lowering is needed and the patient tolerates 5 mg without edema or orthostatic symptoms, a clinician may increase toward 10 mg, though many clinicians prefer adding a second, complementary antihypertensive (such as an ACE inhibitor, ARB, or low-dose thiazide) rather than pushing amlodipine to its ceiling, since edema becomes more common at higher doses.

A large randomized trial in adults 50 and older with hypertension and elevated cardiovascular risk (the SPRINT trial) found that a more intensive blood pressure target reduced cardiovascular events in a subgroup of adults 75 and older, but also came with more treatment-related adverse events such as hypotension and syncope in that older group. The exact event rates from SPRINT are widely cited but should be checked against the original trial publication before being quoted as precise percentages; the directionally important point for this page is that intensive lowering in older adults carries a real trade-off between cardiovascular benefit and short-term harm from overtreatment, which is why titration pace in older patients should be individualized rather than protocol-driven.

What blood pressure target should you use?

There is genuine, unresolved disagreement between major guideline bodies here, and a reader looking for a single number will not find one that applies to everyone.

• The 2017 ACC/AHA hypertension guideline generally supports a target below 130/80 mmHg for non-institutionalized, ambulatory older adults who can tolerate treatment.
• The 2017 ACP/AAFP guideline recommends a less aggressive systolic target, generally below 150 mmHg, for many adults 60 and older, reflecting concern about overtreatment in patients who are frail, have limited life expectancy, or carry heavy polypharmacy burdens.

Both guidelines describe evidence-based positions from accountable professional bodies; they simply weigh the same underlying trial evidence differently for how it applies to frail versus fit older populations. The practical resolution used in most geriatric practice is to individualize: a fit, independent 68-year-old with few comorbidities is a different prescribing decision than a frail 84-year-old with a fall history and multiple medications, even if their office blood pressure readings are identical.

Peripheral edema: the dose-limiting side effect

Peripheral edema is the most common reason older adults stop amlodipine. It results from arteriolar dilation shifting fluid into the interstitial space, not from fluid overload or heart failure, and it is dose-related: the FDA label reports it as more common at 10 mg than at lower doses. Because the mechanism is redistribution rather than volume overload, diuretics are not an effective treatment for amlodipine-related edema and can introduce their own risks (electrolyte disturbance, dehydration, falls) without fixing the underlying problem.

Two approaches are used clinically to manage edema without discontinuing amlodipine:

• Adding an ACE inhibitor or ARB, which dilates the venous side of the circulation and can offset the arteriolar dilation causing the edema. Combination trials using amlodipine with an ACE inhibitor have generally reported lower edema rates than amlodipine alone, though exact comparative rates from any single trial should be verified before being cited numerically.
• Reducing the dose, for example from 10 mg back to 5 mg, which often resolves edema while maintaining useful blood pressure lowering.

Orthostatic hypotension and fall risk

Standing blood pressure measurement (checked after 1 and 3 minutes of standing) is a reasonable routine practice in older adults on any antihypertensive, amlodipine included. Orthostatic hypotension is common in community-dwelling older adults generally, and it is a recognized, modifiable contributor to falls.

Amlodipine's long half-life is a mixed feature in this context. It produces smoother, more gradual blood pressure lowering than shorter-acting dihydropyridines like immediate-release nifedipine, which is one reason the 2023 American Geriatrics Society Beers Criteria does not flag amlodipine itself as potentially inappropriate for older adults, while it does flag immediate-release nifedipine for its sharper hypotensive swings. But the same long half-life means that if hypotension does develop on amlodipine, it can take days to resolve after a dose reduction, because the drug clears slowly. If a patient reports dizziness or unsteadiness, or a standing systolic drop of 20 mmHg or more is documented, dose reduction should generally happen before further workup, not after.

Interactions that matter in polypharmacy

Older adults commonly take multiple prescription medications, and two categories of interaction are worth specific attention with amlodipine.

CYP3A4 inhibitors. Drugs such as diltiazem, clarithromycin, and certain antifungals and antivirals can raise amlodipine blood levels by inhibiting the enzyme that clears it. The FDA label advises caution and closer blood pressure monitoring when amlodipine is combined with strong CYP3A4 inhibitors. In a patient already on a reduced, age-adjusted dose, this kind of interaction can still produce symptomatic hypotension.

Simvastatin dose limit. The FDA has issued a specific safety communication limiting simvastatin to 20 mg daily when it is used together with amlodipine, because the combination raises simvastatin exposure and the risk of muscle toxicity, including rhabdomyolysis. This is a genuine, checkable rule worth confirming any time amlodipine is added to a patient's existing simvastatin regimen, since older patients are often established on higher simvastatin doses before amlodipine is introduced.

Pharmacodynamic stacking. Combining amlodipine with other blood-pressure-lowering drugs, alpha-blockers used for prostate symptoms, or diuretics compounds hypotensive risk in an additive way that is not captured by any single drug interaction warning. Each added antihypertensive-acting drug is a separate opportunity for orthostatic symptoms and falls in an older patient, and medication reconciliation should account for the whole regimen, not just amlodipine in isolation.

Kidney and liver function

No renal dose adjustment is specified for amlodipine, and this is a genuine practical advantage in a population where chronic kidney disease is common. Amlodipine is heavily protein-bound and is not effectively removed by dialysis, and its metabolites are inactive.

Hepatic impairment is different. Because clearance depends on liver metabolism, patients with significant liver disease have prolonged elimination, and the FDA label recommends starting at 2.5 mg with slow titration in this population. Many older patients with mild fatty liver disease or fibrosis fall into a gray zone: the standard 2.5 mg starting dose is reasonable, but pushing above 5 mg should be done cautiously and with clinician oversight.

When deprescribing should be discussed

Deprescribing amlodipine is a reasonable conversation, not a rule, when blood pressure runs persistently low (for example, consistently below 120 mmHg systolic), when orthostatic symptoms appear, or when a patient's overall health status makes the long-term cardiovascular benefit of continued treatment unlikely to be realized within their remaining life expectancy. Geriatric deprescribing frameworks generally support considering dose reduction or discontinuation in these situations, though the exact numeric thresholds used vary by framework and should be treated as guides for discussion rather than fixed cutoffs.

Amlodipine's long half-life means abrupt discontinuation does not cause the rebound hypertension seen with some other antihypertensives (such as clonidine or beta-blockers). A common practical approach is to step down (for example, from 5 mg to 2.5 mg for a couple of weeks) before stopping, and to recheck blood pressure periodically for several weeks afterward to catch any upward trend.

What the evidence supports, and what it does not

Established: The FDA label's recommendation of a 2.5 mg starting dose in patients 65 and older, the lack of a renal dose adjustment, the need for slower titration in hepatic impairment, the simvastatin 20 mg ceiling when combined with amlodipine, and the general pharmacology of a long half-life drug requiring roughly a week to reach steady state are all label-level or regulatory-level facts.

Guideline-recommended but not uniform: Blood pressure targets for older adults are guideline recommendations, not settled facts, and different accountable bodies (ACC/AHA versus ACP/AAFP) reach different conclusions for the same population. A clinician's choice of target for a given patient is a judgment call informed by these guidelines, not a lookup.

Plausible but requiring individual confirmation: Specific numeric claims about how much older age increases amlodipine blood levels, exact edema incidence at each dose in geriatric subgroups, and exact percentage reductions in edema from adding an ACE inhibitor appear in the pharmacology and trial literature, but the specific figures should be verified against the original papers before being used as authoritative numbers in patient-facing or clinical materials. This page intentionally avoids stating those figures as fixed values.

Not established from the material available here: A single "correct" systolic blood pressure number for all adults over 65, a fixed calendar age at which amlodipine should always be deprescribed, and precise comparative edema or mortality percentages from named trials (SPRINT, ASCOT-BPLA, ACCOMPLISH) are referenced in general terms only. Anyone citing exact trial numbers from these studies should pull them from the original trial publications rather than from this summary.

A monitoring and discussion framework for geriatric amlodipine dosing

This framework is intended as a conversation and documentation aid for the clinician-patient visit, not a substitute for individualized clinical judgment.

Before the first prescription

• Confirm seated and standing blood pressure (both arms), ideally at more than one visit.
• Screen the full medication list for CYP3A4 inhibitors and for other blood-pressure-lowering or hypotension-prone drugs (alpha-blockers, diuretics, other antihypertensives).
• Ask about falls in the past year and consider a simple functional test (such as Timed Up and Go) if fall risk is uncertain.
• Check for known hepatic impairment; if present, plan for a slower titration than usual.
• Establish, in conversation with the patient, whether a fit-adult target (below 130/80 mmHg) or a more conservative target (below 150 mmHg systolic) fits this patient's overall health, frailty, and preferences.

Checkpoint at 7 to 14 days after starting or after any dose increase

• Recheck seated and standing blood pressure.
• Ask specifically about dizziness, lightheadedness, unsteadiness, and any near-falls or falls.
• Check for early leg or ankle swelling.
• Do not increase the dose again before this checkpoint, since steady state has not yet been reached.

Stop or hold criteria at any checkpoint

• Standing systolic blood pressure drop of 20 mmHg or more, or standing diastolic drop of 10 mmHg or more, with symptoms.
• New or worsening peripheral edema that concerns the patient or interferes with function.
• A fall or near-fall since the last visit.
• Systolic blood pressure trending below the individualized target with symptoms of hypoperfusion (fatigue, confusion, dizziness).

Escalation vs continued titration

• If blood pressure is above target with no orthostatic symptoms and no edema, titration can proceed on schedule.
• If blood pressure is above target but the patient has orthostatic symptoms, edema, or a recent fall, consider holding the current dose or adding a second, complementary agent rather than increasing amlodipine further.
• If a new drug with CYP3A4-inhibiting potential is added to the regimen, reassess blood pressure sooner than the routine schedule rather than waiting for the next planned visit.

Ongoing surveillance (every visit thereafter)

• Seated and standing blood pressure.
• Review of the full medication list for new interacting drugs.
• Reassessment of whether the original blood pressure target still fits the patient's current health status, since frailty and life expectancy can change over time.

Deprescribing checkpoint (annually, or after a major health change)

• Is blood pressure consistently below the individualized target without treatment intensification elsewhere?
• Has the patient's overall health status, frailty, or life expectancy changed since the target was set?
• Are there new orthostatic symptoms or falls that suggest the current dose is too high?
• If deprescribing is appropriate, plan a gradual step-down and a period of follow-up blood pressure checks afterward, since amlodipine's long half-life does not cause rebound hypertension but the effect of stopping should still be confirmed rather than assumed.

Boundary between label guidance and individualized care. The FDA label sets the starting dose, the dose ceiling, and general cautions about hepatic impairment and drug interactions. It does not set a single blood pressure target, a mandatory titration calendar, or a fixed deprescribing age. Those decisions sit with the clinician and patient, informed by guidelines that themselves disagree, and they should be documented as individualized decisions rather than treated as protocol defaults.